Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein

Audrey Y. Chu(University of Helsinki), Paul M. Ridker(Herlev Hospital), Daniel I. Chasman(Brigham and Women's Hospital), Fredrik Nyberg(National Academy of Medicine), Bryan J. Barratt(AstraZeneca (United Kingdom)), Franco Guilianini(AstraZeneca (United Kingdom))
Circulation Cardiovascular Genetics
January 10, 2012
10.1161/circgenetics.111.961847
Cited by 48

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Biological, clinical and population relevance of 95 loci for blood lipids
|Nature|2010|3.7k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease
|New England Journal of Medicine|1996|2.4k
C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events
|Circulation|2003|2.3k